Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology

Abstract

CCCP testing identified clinically impactful alterations in 64% of cases. Limited coverage and low reimbursement remain barriers, and broader reimbursement policies are needed to adopt pan-cancer NGS testing that benefits patients into clinical practice.